ENBREL
LOE Approachingetanercept
BLASUBCUTANEOUSSYRINGEPriority Review
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ENBREL (etanercept) is tumor necrosis factor receptor blocking activity [moa]. Approved for rheumatoid arthritis, psoriasis, psoriatic arthritis and 2 more indications. First approved in 1998.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENBREL (etanercept) is a fusion protein biologic that functions as a Tumor Necrosis Factor (TNF) receptor blocker, approved in 1998 for subcutaneous injection. It is indicated for rheumatoid arthritis, psoriasis, and juvenile psoriatic arthritis in pediatric patients aged 2 years and older, as well as moderate to severe plaque psoriasis in adults. The drug works by binding and neutralizing TNF-alpha, a key inflammatory cytokine driving autoimmune and inflammatory diseases. As a first-generation TNF inhibitor, ENBREL established the TNF-blocking class and remains a foundational therapy in immunosuppressive treatment.
$0.6BPart D
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications (5)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.